News

Qdolo ™ (tramadol – Athena Bioscience) oral solution, 5mg/mL was approved on Sept. 1, 2020, by the U.S. Food and Drug Administration (FDA). A C-IV controlled substance, it is indicated for treating adults who have severe pain that requires an opioid, but that does not respond to other treatments....

In a new Work Comp Wire article, Chief Sales Officer David Dubrof discusses how strong pharmacy network relationships and clinical oversight are more important for a long-term claims management strategy. Newly appointed myMatrixx Chief Sales Officer, David Dubrof, was featured in the most recent...

myMatrixx, an Express Scripts Company today announced that David Dubrof has been named Chief Sales Officer for the organization. “We’re absolutely thrilled to have David join our team,” said Mike Cirillo, President of myMatrixx. “His 25-plus years of executive management experience in sales,...

myMatrixx assembles a panel of leading industry experts to discuss the impact of COVID-19 on workers' compensation in a virtual presentation for the Express Scripts Outcomes Summer Series.

During June and July, the FDA has issued a series of warnings that some commercial hand sanitizers contain methanol and it has asked a number of manufacturers to recall their products. Also known as wood alcohol, methanol is intended for industrial use in products such as pesticides and solvents....

In a Safety Communication on July 23, 2020, the FDA alerted prescribers, pharmacies and patients of a new requirement for opioid drugs. It is directing drug companies that make opioids for pain relief and for use in treating opioid use disorder to add information on the labels about the use of naloxone....

Workers’ compensation pharmacy spending decreased by 6.1% in 2019, according to new data released today by myMatrixx. Through customized solutions that focus on patient safety and clinical care, myMatrixx provides monitoring and clinical intervention at all phases during the life of a workers’...

In an article for industry publication WorkCompWire, myMatrixx Chief Clinical Officer, Phil Walls, highlighted the key stories and trends coming out of the release of the 2019 Drug Trend Report . The annual report, released on July 8th, provides an in-depth analysis of pharmaceutical data in the...

Preliminary results from a randomized, controlled, open-label, adaptive study on the use of dexamethasone were added to myMatrixx’s “Coronavirus Disease 2019 (COVID-19) – The Search for a Treatment” document. The recovery trial compared a ten day course of dexamethasone 6mg once per day versus...

As development of a vaccine for COVID-19 continues to be a high a priority in the overall effort to control the pandemic, there are currently over a 100 potential vaccines in development. Although commercial availability of a vaccine is still realistically 12 to 18 months away, the “COVID-19 - Searching...